INIS
risks
63%
patients
62%
women
49%
diseases
48%
glucose
42%
levels
39%
data
38%
floors
35%
comparative evaluations
34%
populations
29%
reviews
28%
symptoms
27%
females
27%
sex
26%
muscles
24%
brain
23%
metabolism
21%
plasma
20%
biological markers
20%
diet
20%
adults
20%
men
18%
interventions
18%
kidneys
16%
intake
16%
incidents
16%
insulin
16%
cardiovascular diseases
15%
volume
15%
control
14%
liver
14%
diabetes mellitus
14%
inflammation
12%
adjustments
12%
assessments
11%
quality of life
11%
monitoring
11%
management
11%
lipids
11%
pregnancy
11%
people
11%
humans
10%
nervous system diseases
10%
sensitivity
10%
pain
10%
weight
10%
design
10%
regression analysis
10%
exercise
9%
therapy
9%
vessels
9%
losses
9%
blood pressure
8%
proteins
8%
obesity
8%
cholesterol
8%
range
7%
surveys
7%
surgery
7%
peptides
7%
performance
7%
values
7%
hormones
7%
globulins
7%
fructose
7%
covid-19
7%
recommendations
7%
receptors
7%
guidelines
7%
cost
7%
pulses
7%
urinary tract
7%
hazards
7%
stimulation
6%
concentration
6%
nmr imaging
6%
genes
6%
stiffness
6%
blood
6%
velocity
6%
devices
6%
images
6%
dialysis
6%
resources
6%
education
6%
mortality
6%
urine
6%
metabolites
6%
atherosclerosis
6%
netherlands
6%
hypertension
6%
environment
6%
bladder
5%
food
5%
thickness
5%
sleep
5%
sodium
5%
damage
5%
correlations
5%
layers
5%
Keyphrases
Maastricht
100%
Type 2 Diabetes Mellitus (T2DM)
61%
Urinary Incontinence
35%
Randomized Controlled Trial
22%
Diabetes
21%
Pre-diabetes (pre-DM)
20%
Depressive Symptoms
19%
Cardiovascular Risk
14%
Stress Urinary Incontinence
13%
Pelvic Floor muscle Training
12%
Advanced Glycation End Products
11%
International Continence Society
11%
Physical Activity
10%
Obese Men
10%
Microvascular Dysfunction
10%
Normal Glucose Tolerance
10%
Cardiovascular Disease
10%
Non-alcoholic Fatty Liver Disease (NAFLD)
10%
Meta-analysis
9%
Methylglyoxal
9%
Pelvic Health
9%
Type 2 Diabetic Patients
8%
Quality of Life
8%
Primary Care
8%
Physiotherapy
8%
Vascular Complications
8%
Female Pelvic Floor Dysfunction
8%
Dutch
8%
Cerebral Small Vessel Disease (cSVD)
8%
Pelvic Floor Disorders
7%
Health Centers
7%
Glucose Metabolism Status
7%
Nurse Specialist
7%
Sex Hormone-binding Globulin
7%
Continuous Glucose Monitoring
7%
Dicarbonyls
7%
Postpartum Women
6%
Metformin
6%
Sex Differences
6%
Hepatic Fat
6%
Body Mass Index
6%
Weight Loss
6%
Adult Patients
6%
Pelvic Floor muscles
6%
Electrical Stimulation
6%
Confidence Interval
6%
Older Adults
6%
Cognitive Functioning
6%
Odds Ratio
5%
Netherlands
5%
3-deoxyglucosone
5%
Insulin Sensitivity
5%
Fructose
5%
Retinal Microvasculature
5%
During Pregnancy
5%
Genome-wide Association Study
5%
Risk Factors
5%
Structural Brain Abnormalities
5%
Dietary Weight Loss
5%
Vascular Function
5%
Incident Depression
5%
Conservative Management
5%
Female Urinary Incontinence
5%
Hazard Ratio
5%
Partum
5%
Pelvic Floor
5%
Non-associated
5%
Inflammation
5%
COVID-19
5%
Cognitive Impairment
5%
Terminology Report
5%
Urinary Incontinence in Women
5%
Carotid-femoral Pulse Wave Velocity (cfPWV)
5%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
56%
Diabetes
24%
Impaired Glucose Tolerance
20%
Prevalence
20%
Randomized Controlled Trial
20%
Urine Incontinence
18%
Enuresis
18%
Biological Marker
16%
Depression
15%
Pelvic Floor Dysfunction
15%
Glucose Metabolism
15%
Systematic Review
14%
Physical Activity
14%
Stress Incontinence
13%
Cardiovascular Disease
12%
Continence
12%
Kegel Exercise
11%
Cardiovascular Risk
11%
Pelvic Floor
11%
Cohort Analysis
11%
Pelvis
11%
Pulse Wave Velocity
9%
Meta-Analysis
9%
Cardiovascular System
8%
Glycon
7%
Body Mass Index
7%
Sex Difference
7%
Arterial Stiffness
7%
Quality of Life
7%
Disease
6%
Electrotherapy
6%
Cerebrovascular Disease
6%
Neurodegeneration
6%
Endothelial Dysfunction
5%
Drug Therapy
5%
Methylglyoxal
5%
Hemodialysis
5%
COVID-19
5%
Incontinence
5%
Endothelial Leukocyte Adhesion Molecule 1
5%
Patient with Type 2 Diabetes
5%
Chronic Kidney Disease
5%
Oral Glucose Tolerance Test
5%